Lupin expands its product basket in Japan after Kyowa receives ten product approvals

Lupin Ltd‘s subsidiary in Japan, Kyowa Pharmaceutical Industry Co Ltd has received approvals for 10 products from the Ministry of Health & Labour Welfare, Japan (MHLW) and expects to launch these in July 2008. Lupin had acquired Kyowa in October 2007 and it is currently focusing on enriching its product basket and expanding its therapy width. These fresh approvals will strengthen Lupin's position in the worlds' second largest pharmaceutical market.

These newly registered molecules will significantly add to Kyowa's growth over the next few years. The company will get the advantage of an early entry in the progressive opening up of the generic Pharma market of Japan as it intends to rapidly introduce an array of generic therapies from its global portfolio.